Cover Image
市場調查報告書

搭配診斷技術的全球市場(適應症、區域別) - 市場規模、市佔率、全球動向、企業檔案資料、調查、報告、機會、市場區塊以及預測

Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

出版商 Allied Market Research 商品編碼 305984
出版日期 內容資訊 英文 107 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
搭配診斷技術的全球市場(適應症、區域別) - 市場規模、市佔率、全球動向、企業檔案資料、調查、報告、機會、市場區塊以及預測 Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
出版日期: 2014年06月14日 內容資訊: 英文 107 Pages
簡介

搭配診斷為事前掌握病患對於特定療法的固有治療反應資訊的新時代體外診斷技術,其市場從2013年的11億美元規模之後,以20%的年複合成長率,被期待在2020年達到35億美元的規模。

本報告關注搭配診斷的全球市場,以適應症區域別分析預測今後變化,並彙集發展的促進、限制因素、機會、技術研究、用途開發、競爭環境、主要參與企業等的最新情報。

第1章 簡介

  • 報告內容
  • 主要市場區塊
  • 調查方法
    • 二次情報調查
    • 主要情報取材
    • 分析工具及模式

第2章 報告摘要

第3章 市場概要

  • 市場的定義與範圍
  • 代謝疾病的搭配診斷
  • 搭配診斷法發展的新動向與技術
  • 做為個人化醫療新風潮的搭配診斷
  • 生物標記市場成為搭配診斷相關產業的基石
  • 重要發現
    • 影響搭配診斷市場的主要因素
    • 成功重要策略
  • Poter的五力分析
  • 政府法規
    • 美國食品藥物管理局(FDA)規範
    • 歐洲
    • 日本
    • 中國
  • 價值鏈分析
  • 事例研究
  • 促進因素
    • 個人化醫療的人氣上昇
    • 藥物不良反應(ADR)的案例增加
    • 隨著生物標記的發現伴隨藥劑標的的增加
    • FDA快速認可的共同開發藥劑的成功擴大
    • 技術進步
    • 疾病發生率的提高
  • 限制因素
    • 高額的藥劑研發成本
      • 經濟與科學阻礙
  • 機會
    • 神經退化性疾病治療的機會
    • 遺傳突變的搭配診斷

第4章 搭配診斷的全球市場 - 適應症別

  • 癌症
  • 發炎和自體免疫疾病
  • 心血管疾病的搭配診斷
  • 中樞神經系統障礙的搭配診斷
  • 病毒性疾病的搭配診斷檢查
  • 其他

第5章 搭配診斷的全球市場 - 技術別

  • 搭配診斷技術市場 - 區域別
  • 免疫組織化學
  • 分子診斷
  • 蛋白質體學
  • 轉錄體學
  • 代謝學
  • 分子系統進化學
  • 其他用途市場
    • 藥理基因體學
    • 藥理蛋白質體學
    • 生物資訊學的其他用途市場 - 區域別

第6章 搭配診斷的全球市場 - 區域別

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 企業檔案資料(企業概要、速覽、業績、策略動向及發展、SWOT分析)

  • Qiagen
  • Dako (Agilent Technologies)
  • Roche
  • Abbott Laboratories, Inc.
  • BioMerieux
  • Ventana Medical Systems
  • Myriad Genetics, Inc.
  • Resonance Health Ltd
  • Leica Microsystems
  • Life Technologies
目錄
Product Code: DI 14135

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market. Opportunities for this market lie in developing companion diagnostics for various central nervous system conditions and hereditary conditions.

Companion Diagnostics Indication Market Analysis

Companion diagnostics is segmented on the basis of its use for indications such as oncology, cardiovascular conditions, central nervous system indications, inflammation and virology. Oncology is the highest revenue generating segment, as majority of the companion diagnostics have been developed for detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic.

Companion Diagnostics Technology Market Analysis

Companion diagnostics technology market is segmented into Immunohistochemistry and Molecular diagnostics. Molecular diagnostics would be the fastest growing and highest revenue generator, mainly due to the use of techniques such as real time PCR, In Situ Hybridization and next generation sequencing. Other factors contributing to the growth is technological advancements in molecular diagnostics, which has resulted in increased accuracy and precision and also reduced cost of testing using these methods.

Companion Diagnostics Geography Market Analysis

Companion Diagnostics market has been segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America has the major market share of 43.97% followed by Europe, which accounted for about 38% of the overall CD market in 2013. North America and Europe together accounted for over 82% in the global CD market in 2013 and they would continue to be the major markets through 2020. This is mainly due to the increasing incidence of cancer and other diseases and higher health care awareness in these regions.

Competitive Analysis

A study of some of the key players has showed that majority of the companies in this market are focusing on collaborations with drug companies. Companion diagnostics is a emerging market and companies are collaborating with drug companies to develop companion diagnostics for their pipeline drugs, which are in developing phase. Approvals for companion diagnostics are the second most popular strategy. Companies profiled in this report include Dako (Agilent Technologies), Qiagen, Roche, Abbott Laboratories, Inc., Ventana Medical Systems, bioMerieux, Myriad Genetics, Inc., Resonance Health Ltd., Leica Microsystems, and Life Technologies.

High Level Analysis

The report is focusing on the trends in technology and diagnosis of various indications, which are driving the growth of the companion diagnostics market. Analysis of the market based on porters five force model shows that the bargaining power of the suppliers is high as the products produced are highly differentiated. The threat of new entrants is low as significant research and development is required for developing diagnostic tests. Apart from the R&D requirements, the investment required is also high. These factors make it difficult for new companies to enter the market. The threat of substitutes is low in this market as companion diagnostics are developed for specific biomarkers and the products are highly differentiated. Competition in this market is moderate as the market is still emerging and there are a few companies in the market. Government regulations are favoring use of companion diagnostics for determining a particular treatment. Companies are focusing on collaborations with pharmaceutical companies as a key strategy to gain competitive advantage.

Reason for doing the study

Companion diagnostics are an important aspect of the personalized treatment approach and are essential for predicting the therapeutic response to a particular drug. With increasing awareness among the population and rising incidences of cancer, companion diagnostics would become an essential factor for targeted therapeutic approach. More and more companies are developing targeted therapeutics products and companion diagnostics is an integral part of their strategy.

KEY BENEFITS

  • In-depth analysis of the companion diagnostic market by technology and indications give a clear idea of the scope of this market
  • Analysis of the market by geography would help in making region specific plans
  • Estimations for period of 2013 to 2020 have been given, taking into consideration the current market scenario and future trends, which would give a clearer picture of the potential of the market
  • Porter's five force model and SWOT analysis would help in a deeper understanding of the market and help in making strategic decisions
  • Top factors impacting the market would help in making decisions for business development

KEY DELIVERABLES

MARKET BY INDICATIONS

  • Oncology
  • Cardiovascular
  • Central Nervous System
  • Auto immune & Inflammation
  • Virology
  • Others

MARKET BY TECHNOLOGY

  • Immunohistochemistry
  • Molecular diagnostics
  • In situ Hybridization
  • FISH
  • CISH
  • Real time PCR
  • Gene Sequencing

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific
  • LAMEA

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Research methodology
    • 1.3.1. Secondary research
    • 1.3.2. Primary research
    • 1.3.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

CHAPTER 3 - MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Companion Diagnostics for Metabolic Diseases
  • 3.3. Novel trends and technologies in companion diagnostics assay development
  • 3.4. Companion diagnostics as a new trend in personalized medicine
  • 3.5. Biomarkers market as basis for the companion diagnostics industry
  • 3.6. Key Findings
    • 3.6.1. Top Factors Impacting The Companion Diagnostic Market
    • 3.6.2. Top Winning Strategies
  • 3.7. Porter's five forces analysis
    • 3.7.1. High switching cost leads to higher bargaining power of suppliers
    • 3.7.2. Highly differentiated products leads to lower bargaining power of buyers
    • 3.7.3. Specificity of diagnostics lowers the threat of substitutes
    • 3.7.4. Higher capital investment leads to lesser threat of entrants
    • 3.7.5. Few competitors leads to low competition among players
  • 3.8. Government Regulations
    • 3.8.1. FDA regulations
    • 3.8.2. Europe
    • 3.8.3. Japan
    • 3.8.4. China
  • 3.9. Value Chain Analysis
  • 3.10. Case Study
  • 3.11. Drivers
    • 3.11.1. Increased popularity of Personalized medicine
    • 3.11.2. Increasing cases of adverse drug reactions(ADRs)
    • 3.11.3. Increase in the Discovery of Biomarkers as drug targets.
    • 3.11.4. Rising success of co-development drugs speedily approved by the FDA
    • 3.11.5. Technological advancements
    • 3.11.6. Rising incidences of diseases
  • 3.12. Restraints
    • 3.12.1. High Cost in research and development of drugs
      • 3.12.1.1. Economic and scientific obstacles
    • 3.12.2. Opportunities
      • 3.12.2.1. Opportunities in treatment of neurodegenerative diseases
      • 3.12.2.2. Companion diagnostics for hereditary mutations

CHAPTER 4 - GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATIONS

  • 4.1. Oncology
    • 4.1.1. Companion diagnostics oncology market by geography,
    • 4.1.2. Breast Cancer
      • 4.1.2.1. companion diagnostics breast cancer market by geography
    • 4.1.3. Lung Cancer
      • 4.1.3.1. companion diagnostics lung cancer market by geography
    • 4.1.4. Colorectal Cancer
      • 4.1.4.1. companion diagnostics Colorectal Cancer market by geography
    • 4.1.5. Gastric cancer
      • 4.1.5.1. companion diagnostics Gastric Cancer market by geography
    • 4.1.6. Melanomas
      • 4.1.6.1. companion diagnostics Melanoma market by geography
  • 4.2. Inflammation and Autoimmune diseases
    • 4.2.1. Companion diagnostics inflammation market by geography
  • 4.3. Companion diagnostics in cardiovascular diseases
    • 4.3.1. Companion diagnostics tests for warfarin
    • 4.3.2. Companion diagnostics cardiovascular market by geography
  • 4.4. Companion diagnostics in CNS disorders
    • 4.4.1. Companion diagnostics CNS market by geography
  • 4.5. Companion diagnostics tests in virology diseases
    • 4.5.1. Companion diagnostics virology market by geography
  • 4.6. Others
    • 4.6.1. Companion diagnostics others market by geography

CHAPTER 5 - GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY

  • 5.1. Companion diagnostics technology market by geography
  • 5.2. Immunohistochemistry
    • 5.2.1. Companion diagnostics Immmunohistochemistry market by geography
  • 5.3. Molecular Diagnostics
    • 5.3.1. Companion diagnostics molecular diagnostics market by types
    • 5.3.2. Companion diagnostics Molecular Diagnostics market by geography
    • 5.3.3. In-situ Hybridization
      • 5.3.3.1. Fluorescent In-situ Hybridization(FISH)
      • 5.3.3.2. CISH (Chromogenic In-Situ Hybridization)
      • 5.3.3.3. Companion diagnostics In situ Hybridization market by geography
    • 5.3.4. Real Time PCR
      • 5.3.4.1. Companion diagnostics RT PCR market by geography
    • 5.3.5. Gene Sequencing
      • 5.3.5.1. Companion diagnostics Sequencing market by geography
    • 5.3.6. Others
      • 5.3.6.1. Others molecular companion diagnostics market by geography

CHAPTER 6 - GLOBAL COMPANION DIAGNOSTICS BY GEOGRAPHY

  • 6.1. North America
    • 6.1.1. Companion diagnostics North America market by indication
  • 6.2. Europe
    • 6.2.1. Companion diagnostics Europe market by indication
  • 6.3. Asia Pacific
    • 6.3.1. Companion diagnostics Asia Pacific market by indication
  • 6.4. RoW
    • 6.4.1. Companion diagnostics RoW market by indication

CHAPTER 7 - COMPANY PROFILES

  • 7.1. Qiagen
    • 7.1.1. Company Overview:
    • 7.1.2. Company Snapshot
    • 7.1.3. Business Performance
    • 7.1.4. Strategy move and development
      • 7.1.4.1. Principal strategies Collaborations
      • 7.1.4.2. Secondary Strategies Approval
    • 7.1.5. SWOT Analysis of Qiagen
  • 7.2. Dako (Agilent Technologies)
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Business Performance
    • 7.2.4. Strategic Moves and Development
      • 7.2.4.1. Principal strategies Collaboration
      • 7.2.4.2. Secondary Strategies Approval
    • 7.2.5. SWOT Analysis of Dako
  • 7.3. Roche
    • 7.3.1. Company overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Business Performance
    • 7.3.4. Strategies move and development
    • 7.3.5. SWOT analysis of Roche
  • 7.4. Abbott Laboratories, Inc.
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Business Performance
    • 7.4.4. Principal Strategies Collaboration
    • 7.4.5. SWOT Analysis of Abbot
  • 7.5. BioMerieux
    • 7.5.1. Company Overview
    • 7.5.2. Company snapshot:
    • 7.5.3. Business Performance
    • 7.5.4. Strategies and development Approval
    • 7.5.5. SWOT Analysis of BioMerieux,
  • 7.6. Ventana Medical Systems
    • 7.6.1. Company Profile
    • 7.6.2. Company Snapshot
    • 7.6.3. Business Performance
    • 7.6.4. Strategies and development
    • 7.6.5. SWOT Analysis of Ventana
  • 7.7. Myriad Genetics, Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company snapshot
    • 7.7.3. Business Performance
    • 7.7.4. Strategies and development
    • 7.7.5. SWOT Analysis of Myraid
  • 7.8. Resonance Health Ltd
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Strategies move and development
    • 7.8.4. SWOT Analysis of Ferriscan
  • 7.9. Leica Microsystems
    • 7.9.1. Company overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Strategies move and Development
    • 7.9.4. SWOT Analysis of Leica Microsystems
  • 7.10. Life Technologies
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Business performance
    • 7.10.4. Strategies move and Development
    • 7.10.5. SWOT Analysis of Life Technologies

LIST OF TABLES:

  • TABLE 1: GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2013-2020 ($MILLION)
  • TABLE 2: COMPANION DIAGNOSTICS INDICATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 3: GLOBAL COMPANION DIAGNOSTICS MARKET BY ONCOLOGY, 2013-2020, ($MILLION)
  • TABLE 4: COMPANION DIAGNOSTICS ONCOLOGY MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
  • TABLE 5: COMPANION DIAGNOSTICS BREAST CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 6: COMPANION DIAGNOSTICS LUNG CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 7: COMPANION DIAGNOSTICS COLORECTAL CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 8: COMPANION DIAGNOSTICS GASTRIC CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 9: COMPANION DIAGNOSTICS MELANOMA MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 10: COMPANION DIAGNOSTICS INFLAMMATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 11: COMPANION DIAGNOSTICS CARDIOVASCULAR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 12: COMPANION DIAGNOSTICS CNS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 13: COMPANION DIAGNOSTICS VIROLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 14: COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 15: COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY TECHNOLOGY 2013-2020 ($MILLION)
  • TABLE 16: COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 17: COMPANION DIAGNOSTICS IMMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 18: COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY TYPES 2013-2020 ($MILLION)
  • TABLE 19: COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 20: COMPANION DIAGNOSTICS IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 21: COMPANION DIAGNOSTICS RT PCR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 22: COMPANION DIAGNOSTICS SEQUENCING MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 23: OTHERS MOLECULAR COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 24: COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 25: COMPANION DIAGNOSTICS NORTH AMERICA MARKET, 2013-2020 ($MILLION)
  • TABLE 26: COMPANION DIAGNOSTICS EUROPE MARKET, 2013-2020 ($MILLION)
  • TABLE 27: COMPANION DIAGNOSTICS ASIA-PACIFIC MARKET, 2013-2020 ($MILLION)
  • TABLE 28: COMPANION DIAGNOSTICS ROW MARKET, 2013-2020 ($MILLION)
  • TABLE 29: QIAGEN SNAPSHOT
  • TABLE 30: DAKO COMPANY SNAPSHOT
  • TABLE 31: ROCHE COMPANY SNAPSHOT
  • TABLE 32: ABBOTT COMPANY SNAPSHOT
  • TABLE 33: BIOMERIEUX COMPANY SNAPSHOT
  • TABLE 34: VENTANA COMPANY SNAPSHOT
  • TABLE 35: MYRIAD COMPANY SNAPSHOT
  • TABLE 36: RESONANCE COMPANY SNAPSHOT
  • TABLE 37: LEICA COMPANY SNAPSHOT
  • TABLE 38: LIFE TECHNOLOGIES COMPANY SNAPSHOT

LIST OF FIGURES:

  • FIG.1: OMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE
  • FIG.2: FFECTIVENESS OF COMPANION DIAGNOSTICS IN LUNG CANCER PATIENTS
  • FIG.3: IST BIOMARKERS AND THE COMPANION DIAGNOSTICS FOR VARIOUS DISEASES
  • FIG.4: OP FACTORS IMPACTING THE COMPANION DIAGNOSTIC MARKET
  • FIG.5: OP WINNING STRATEGIES
  • FIG.6: ALUE CHAIN ANALYSIS
  • FIG.7: INANCIAL REVENUES BY BUSINESS UNITS (2013)
  • FIG.8: INANCIAL REVENUES BY GEOGRAPHY(2013)
  • FIG.9: WOT ANALYSIS OF QIAGEN
  • FIG.10: INANCIAL REVENUE OF DAKO, BY SEGMENT (2012)
  • FIG.11: WOT ANALYSIS OF DAKO
  • FIG.12: INANCIAL REVENUE OF DAKO, BY SEGMENT
  • FIG.13: INANCIAL REVENUE OF DAKO, BY GEOGRAPHY
  • FIG.14: WOT ANALYSIS OF ROCHE
  • FIG.15: EVENUE BY BUSINESS SEGMENTS
  • FIG.16: EVENUE BY GEOGRAPHY
  • FIG.17: WOT ANALYSIS OF ABBOTT
  • FIG.18: INANCIAL REVENUES BY GEOGRAPHY
  • FIG.19: INANCIAL REVENUES BY TECHNOLOGY
  • FIG.20: WOT ANALYSIS OF BIOMERIEUX
  • FIG.21: WOT ANALYSIS OF VENTANA
  • FIG.22: EVENUE BY DIAGNOSTIC TYPE
  • FIG.23: WOT ANALYSIS OF MYRAID
  • FIG.24: WOT ANALYSIS OF FERRISCAN
  • FIG.25: WOT ANALYSIS OF LEICA MICROSYSTEMS
  • FIG.26: EVENUE BY END MARKETS
  • FIG.27: WOT ANALYSIS OF LIFE TECHNOLOGIES
Back to Top